Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel Inhibitors against Neuroblastoma

01.07.2013
Neuroblastoma is a malignant cancer, which occurs chiefly in infants. University of Würzburg scientists now present novel inhibitors able to suppress the growth of these tumors in the journal "Cancer Cell".
Neuroblastoma is one of the most common cancers in children up to one year of age. Neuroblastomas develop when certain nerve cells degenerate and form sizable lumps – in most cases in the abdomen of the child. About 130 cases of the disease are diagnosed each year in Germany.

In contrast to many other types of cancer, neuroblastomas sometimes heal spontaneously. In most patients, this type of cancer can be easily treated with conventional drugs. However, the chances of recovery and survival are slim in 20 percent of the cases. The reason: The tumors form metastases that don't much respond to conventional drugs.

Why the tumor becomes aggressive

"The most important factor for a poor prognosis is an amplification of the MYCN gene," says Professor Martin Eilers at the Biocenter of the University of Würzburg. This leads to an increased production of the MYCN protein, which is assumed to be responsible for the aggressive growth and the resistance to therapy of the tumors.

The MYCN protein stimulates cell growth. In normal cells, it can only be active for a short while, because it is quickly degraded. The situation is different in neuroblastomas: There, the protein is protected from fast degradation, because it is bound to a partner protein (Aurora-A). This was shown by Martin Eilers' study group in 2009.

How the novel inhibitors work

Together with an international team, the Würzburg study group has now made further progress in this research: They identified novel inhibitors that are able to disrupt the complex of Aurora-A and MYCN. If aggressive neuroblastomas are treated with these inhibitors, they cease to grow. At least, this is the result of tests in a mouse model.
"This might show the way to the development of new and better drugs against this aggressive tumor," says Eilers. According to the professor, other long-known inhibitors of the Aurora-A protein are already being tested in the first clinical trials in the USA.

The inhibitors of Aurora-A are promising for the treatment of other types of cancer as well: The fatal complex of Aurora-A and the MYCN protein is also present in particularly aggressive prostate carcinomas.

"Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma", Markus Brockmann, Evon Poon, Teeara Berry, Anne Carstensen, Hedwig E. Deubzer, Lukas Rycak, Yann Jamin, Khin Thway, Simon P. Robinson, Frederik Roels, Olaf Witt, Matthias Fischer, Louis Chesler, Martin Eilers, Cancer Cell, 20 June 2013, DOI 10.1016/j.ccr.2013.05.005

Contact person

Prof. Dr. Martin Eilers, Biocenter at the University of Würzburg, T +49 (0)931 888-4442, martin.eilers@biozentrum.uni-wuerzburg.de

Gunnar Bartsch | Uni Würzburg
Further information:
http://www.uni-wuerzburg.de

Further reports about: Biocenter Cancer MYCN Small Molecule aurora-A nerve cell neuroblastoma types of cancer

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>